Merck Enlists Life Tech to Develop Companion Test for Cancer Drug, Other Pipeline Opportunities | GenomeWeb

Merck Serono has engaged Life Technologies to help it advance molecular diagnostics that can pick out best responders to its treatments.

The collaboration is initially centered on an unnamed oncology drug, according to the partners. However, the deal holds opportunities for Life Tech to help Merck advance multiple drugs in a variety of therapeutic areas with a personalized, biomarker-driven strategy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.